Literature DB >> 32102267

Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.

Gils Roex1, Tom Feys2, Yves Beguin3, Tessa Kerre4, Xavier Poiré5, Philippe Lewalle6, Peter Vandenberghe7, Dominique Bron6, Sébastien Anguille1,8.   

Abstract

Chimeric antigen receptor (CAR)-T-cell therapy is an innovative form of adoptive cell therapy that has revolutionized the treatment of certain hematological malignancies, including B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL). The treatment is currently also being studied in other B-cell neoplasms, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). CD19 and B-cell maturation antigen (BCMA) have been the most popular target antigens for CAR-T-cell immunotherapy of these malignancies. This review will discuss the efficacy and toxicity data from the pivotal clinical studies of CD19- and BCMA-targeted CAR-T-cell therapies in relapsed/refractory B-cell malignancies (NHL, ALL, CLL) and MM, respectively.

Entities:  

Keywords:  B-cell malignancies; BCMA; CAR-T cells; CD19; immunotherapy

Year:  2020        PMID： 32102267     DOI： 10.3390/pharmaceutics12020194

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN： 1999-4923            Impact factor:   6.321


  15 in total

Review 1.  Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.

Authors:  Mona Kamal; Jacinth Joseph; Uri Greenbaum; Rachel Hicklen; Partow Kebriaei; Samer A Srour; Xin Shelly Wang
Journal:  Transplant Cell Ther       Date:  2021-01-07

Review 2.  Transmembrane Activator and CAML Interactor (TACI): Another Potential Target for Immunotherapy of Multiple Myeloma?

Authors:  Shengli Xu; Kong-Peng Lam
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

Review 3.  Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword.

Authors:  Anthony M Battram; Mireia Bachiller; Beatriz Martín-Antonio
Journal:  Int J Mol Sci       Date:  2020-06-18       Impact factor: 5.923

Review 4.  B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.

Authors:  Hanley N Abramson
Journal:  Int J Mol Sci       Date:  2020-07-22       Impact factor: 5.923

Review 5.  Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.

Authors:  Weiqi Yan; Zhuojun Liu; Jia Liu; Yuanshi Xia; Kai Hu; Jian Yu
Journal:  Biomed Res Int       Date:  2020-10-01       Impact factor: 3.411

6.  SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.

Authors:  Jia Wei; Jianping Zhao; Meifang Han; Fankai Meng; Jianfeng Zhou
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

7.  Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.

Authors:  Gils Roex; Marijke Timmers; Kristien Wouters; Diana Campillo-Davo; Donovan Flumens; Wilfried Schroyens; Yiwei Chu; Zwi N Berneman; Eva Lion; Feifei Luo; Sébastien Anguille
Journal:  J Hematol Oncol       Date:  2020-12-03       Impact factor: 17.388

8.  Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs.

Authors:  Adam J Johnson; Jia Wei; James M Rosser; Annette Künkele; Cindy A Chang; Aquene N Reid; Michael C Jensen
Journal:  Cancer Immunol Res       Date:  2021-07-09       Impact factor: 11.151

Review 9.  Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Leonard Jeff Harris; Kruti Patel; Michael Martin
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

10.  Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia.

Authors:  Pinar Ataca Atilla; Mary K McKenna; Haruko Tashiro; Madhuwanti Srinivasan; Feiyan Mo; Norihiro Watanabe; Brian Wesley Simons; Alexandra McLean Stevens; Michele S Redell; Helen E Heslop; Maksim Mamonkin; Malcolm K Brenner; Erden Atilla
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.